Production (Stage)
Leap Therapeutics, Inc.
LPTX
$0.393
-$0.0022-0.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.01M | 3.01M | 2.94M | 3.37M | 3.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.86M | 16.13M | 18.35M | 21.00M | 14.58M |
| Operating Income | -15.86M | -16.13M | -18.35M | -21.00M | -14.58M |
| Income Before Tax | -15.44M | -15.55M | -17.47M | -20.36M | -13.82M |
| Income Tax Expenses | -- | -123.00K | 708.00K | -- | -- |
| Earnings from Continuing Operations | -15.44M | -15.43M | -18.18M | -20.36M | -13.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.44M | -15.43M | -18.18M | -20.36M | -13.82M |
| EBIT | -15.86M | -16.13M | -18.35M | -21.00M | -14.58M |
| EBITDA | -15.86M | -16.13M | -18.35M | -21.00M | -14.57M |
| EPS Basic | -0.37 | -0.38 | -0.44 | -0.52 | -0.51 |
| Normalized Basic EPS | -0.23 | -0.47 | -0.26 | -0.32 | -0.32 |
| EPS Diluted | -0.37 | -0.38 | -0.44 | -0.52 | -0.51 |
| Normalized Diluted EPS | -0.23 | -0.47 | -0.26 | -0.32 | -0.32 |
| Average Basic Shares Outstanding | 41.27M | 41.25M | 41.21M | 39.12M | 27.01M |
| Average Diluted Shares Outstanding | 41.27M | 41.25M | 41.21M | 39.12M | 27.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |